Latest Content

Resmetirom showed comparable MASH resolution and fibrosis improvement in patients on GLP-1 RA or SGLT2i therapy and those on resmetirom alone.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Performance on Medicare Star Ratings medication adherence measures is significantly tied to performance on the intermediate outcome and statin process measures.

Finerenone significantly reduced UACR in type 1 diabetes with chronic kidney disease, offering new hope for treatment.

CMS introduced the GENEROUS Model to reduce Medicaid drug costs, enhance access, and improve health outcomes for beneficiaries starting in 2026.

The FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro), offering a new treatment for high-risk smoldering multiple myeloma.

The White House announced significant drug pricing cuts for GLP-1s for diabetes and obesity for Medicare and Medicaid beneficiaries and on TrumpRx.

Medicare Advantage plans that place greater restrictions on home health agency care delivery may have more adverse patient outcomes than plans that provide episodic payments.

The efficacy of immune checkpoint inhibitors was found in patients with both HIV and non–small cell lung cancer (NSCLC), though more inclusion of people with HIV is needed in future studies.